In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reliance GeneMedix PLC

Division of Reliance Life Sciences
www.genemedix.com

Latest From Reliance GeneMedix PLC

Biosimilars: A New Kind Of Innovation

The lesson from first-generation biosimilars is that these aren't just small-molecule style copies. They require significant clinical and commercial support to overcome prescriber skepticism. For those lining up to tap into the next-generation opportunity, biosimilars represent a new kind of innovation, where the novelty lies in a drug's value-focused pricing, quality, cost-effective production, and in peripherals such as support-services and means of delivery. Although biosimilar market dynamics will vary from molecule to molecule, this emphasis on price and value rather than scientific breakthrough exemplifies a new definition of innovation in the biopharma sector.

BioPharmaceutical Europe

Biosimilars: EMEA Wants Approvals

European regulators’ guidelines on biosimilars show that they are serious about quickly approving cheaper follow-on biologics. The hurdles may come thereafter.
BioPharmaceutical Legal Issues

Trade Sales Trump IPOs, Even for Platforms

Europe's summertime flurry of private biotech sell-offs points to growing pragmatism among management and VCs, and still-poor valuations on the public markets. Firms which haven't already considered the trade sale opportunity should do so--even early-stage, pre-product platform groups.
BioPharmaceutical Strategy

FDA Hesitates on Biogenerics

A long-awaited Food and Drug Administration (FDA) workshop held in mid-September, highlighted just how far the agency is from establishing a regulatory path for generic copies of biologics. Although it yielded few surprises, the meeting provided a concentrated public forum for interested parties to present in-depth views of all sides of the issue--an unusual event in itself
BioPharmaceutical Asia Pacific
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Reliance Life Sciences
  • Senior Management
  • Vinay Ranade, CEO
  • Contact Info
  • Reliance GeneMedix PLC
    Phone: (44) 5793 23572
    IDA Business & Technology Park
    Tullamore ,
    Ireland
Advertisement
Advertisement
UsernamePublicRestriction

Register